Previously, a panel of monoclonal antibodies recognizing epitopes in four antigenic sites on the haemagglutinin-neuraminidase (HN) glycoprotein of the Australia-Victoria strain of Newcastle disease virus were used in strain comparisons. Epitopes in three sites were found to be conserved while the epitope recognized by the single antibody to site 3 was not. A new panel of antibodies is described, two of which bind to epitopes in site 3 and six of which bind to a site (site 1,4) that overlaps with sites 1 and 4 as determined by analyses of variants, temperature-sensitive mutants, and strains by assays of neutralization of infectivity and binding in a radioimmunoassay. Neutralization of heterologous strains with the panel of antibodies revealed that both new site 3 epitopes are also highly divergent, while three additional epitopes outside site 3 (those in site 1,4) are highly conserved. The new site 3 antibodies can bind to virions of several heterologous strains without neutralizing infectivity. Thus, of the 10 epitopes we have now examined, all of three in site 3 are specific with respect to neutralization of infectivity for the homologous strain, while all of seven in other sites are conserved in heterologous strains. This suggests that the strain specificity originally described for a single site 3 epitope is, instead, a property of a much more extensive, poorly conserved domain on the HN molecule. 0000-7077 © 1986 SGM Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11 On: Fri, 21 Dec 2018 15:27:52 1394 R. M. IORIO AND OTHERS Bratt, 1983 ). Furthermore, by analysing neutralization-resistant variants selected with these MAbs as well as previously described (Peeples & Bratt, 1982) temperature-sensitive (ts) mutants
INTRODUCTION
Wide variations in virulence patterns and disease patterns ranging from mild upper respiratory tract infections to severe central nervous system involvement are exhibited by different isolates of the paramyxovirus, Newcastle disease virus (NDV). Polyvalent sera specific for either of the viral glycoproteins, i.e. the haemagglutinin-neuraminidase glycoprotein (HN), responsible for attachment, or the fusion glycoprotein (F), responsible for penetration, can neutralize infectivity (Merz et al., 1980; Scheid & Choppin, 1973 . Despite their extreme variation, all NDV isolates are serotypically indistinguishable by polyvalent sera to either protein (Avery & Niven, 1979; Pennington, 1978) to the extent that new isolates of NDV are, indeed, identified by their recognition by polyvalent sera. However, hybridoma and monoclonal antibody (MAb) technology (K6hler & Milstein, 1975) has now made possible the exploration of strain-specific variation at the level of individual antigenic determinants. Russell & Alexander (1983) were able to place 40 NDV strains into eight groups on the basis of their interaction with MAbs to two antigenic sites as well as their biology and place of isolation. Using a single MAb to each of the four antigenic sites on HN (Iorio & Bratt, 1983) , we identified a site 3 epitope recognized by antibody HN 3a which is specific for the H N of the Australia-Victoria (AV) strain of NDV; epitopes studied within each of the other three antigenic sites were generally highly conserved (Iorio et al., 1984) . Similarly, Nishikawa et al. (1983) have identified a strain-specific epitope on the HN of a different strain of NDV. Using a new panel of MAbs we have now identified a site (designated 1,4) which overlaps the originally described sites 1 and 4 (Iorio & with lesions in the HN gene, we have demonstrated that the new panel also includes two additional site 3 MAbs, which identify epitopes distinct from each other as well as that defined by the originally described antibody HN3a (Iorio & Bratt, 1985) . Like the HN3a epitope, these newly described site 3 epitopes have been shown to be strain-specific with respect to neutralization, while all tested additional epitopes outside site 3 have been shown to be highly conserved. Thus, the extensive variation originally observed for a single epitope in site 3 actually reflects a property of a much more extensive domain within that site. Furthermore, the MAbs to each of these site 3 epitopes, in several instances, fail to neutralize infectivity despite binding to virions. -Victoria, 1932 ), F (NJ-Roakin, 1946 , IM (Italy-Milano, 1945) , IS (Iowa-Salsbury, 1949 ), L (L-Kansas, 1948 and RO (California RO, 1944) Temperature-sensitive mutant. The ts mutant BC3 was isolated from strain AV (Tsipis & Bratt, 1976) and previously characterized in our laboratory (Peeples & Bratt, 1982) .
METHODS

Virus strains. Virulent strains AV (Australia
Variant isolation. The large persistent fractions of virus surviving treatment with any of our MAbs necessitated the use of a protocol for the selection of antigenic variants using a rabbit anti-mouse immunogtobulin (RAM) treatment to neutralize sensitized, but still infectious, viral particles. This protocol and the screening procedure to identify variants have been described previously (Iorio & Bratt, 1985) .
Virus stock preparation. All strains, variants and the ts mutant were grown in the allantoic sac of 10-day-old embryonated hen eggs at 37 °C from stocks of virus one passage from cloning (Bratt & Gallaher, 1969) . Allantoic fluid for neutralization studies was harvested after the death of the majority of the embryos. For radioimmunoassays (RIA), virus was purified and concentrated from allantoic fluid as described previously (Clavell & Bratt, 1972; Weiss & Bratt, 1974) . Protein was determined by the method of Lowry et al. (1951) .
Cell culture. Primary and secondary chicken embryo cells were prepared and maintained in standard medium as described previously (Bratt & Gallaher, 1969; Hightower & Bratt, 1974) . Confluent secondary cultures (24 to 48 h after plating) in 60 mm tissue culture dishes were used for plaque titrations.
Hybridomas and MAbs. The immunization of BALB/c mice, the preparation, screening (by RIA and fluorescence) and cloning of hybridomas, the production of ascites, and the estimation of antibody concentration in ascites fluid have all been described previously (Iorio & Bratt, 1983) . Hybridoma HN1,4a, a gift of Dr M. E. Peeples, was isolated from a CAF~ mouse. lsotype determinations. Isotypes of MAbs were determined in Ouchterlony double immunodiffusion gels, using isotype-specific antisera (Litton Bionetics, Kensington, Md., U.S.A.) and hybridoma supernatants were concentrated using Centricon-30 microconcentrators (Amicon).
Solid-phase RIA. Virions disrupted by detergent and high salt served as the antigen for screening of hybridoma supernatants as described previously (Iorio & Bratt, 1983) .
For the determination of MAb binding to different NDV strains, intact virions were used and antibody was added in serial threefold dilutions of ascites fluid from an initial dilution of 1 : 100 (Iorio et al., 1984) . ~ zSI-labelled rabbit anti-mouse Ig kappa chain antibody was kindly provided by Dr R. T. Woodland.
Immunoprecipitation and polyacrylamide gel electrophoresis (PAGE) . MAb specificity was determined by immunoprecipitation from [35S]methionine-labelled infected Chinese hamster ovary (CHO) cell lysates (Chatis & Morrison, 1981) using rabbit anti-mouse immunoglobulin beads (Bio-Rad) as described previously (Iorio & Bratt, 1983) . Immunoprecipitates were resolved by electrophoresis in 10% SDS-polyacrylamide slab gels (Laemmli, 1970) . The gels were soaked in Autofluor (National Diagnostics, Somerville, N.J., U.S.A.), dried and exposed to Kodak Royal X-Omat film.
Haemagglutination (HA) inhibition. Titrations were performed in the Titertek system (Flow Laboratories) using twofold dilutions of ascites fluid to inhibit 4 HA units of virus as described previously (lorio & Bratt, I984c) . The reciprocal of the endpoint dilution was taken as the titre and is expressed as mg of antibody per ml.
Competition antibody binding (CAB) assays. An ELISA was used to determine the site specificity of MAbs. One ~tg of intact virions was dried on to each well of a microtitre plate which was then washed with FA buffer (Difco Laboratories) and blocked by a 2 h incubation with 2 % gammaglobulin-free horse serum (Gibco). Fifty ~tl of serial twofold dilutions of a 1 mg/ml preparation of competing MAb was added for 1 h at 37 °C. After washing, 50 p.1 of IP: 54.70.40.11
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Variable epitopes in HN of NDV 1395 horseradish peroxidase (HRP)-conjugated (Wilson & Nakane, 1978) MAb was added for 1 h at 37 °C. Plates were again washed and 50 I~1 of substrate [2 mM-2,2'-azinodi-(3-ethylbenzthiazoline sulphonic acid), 2.4 mM-H202 in 0.1 M-citrate adjusted to pH 4.0 with glycine-HC1] was added. The A414 was then read after 10 rain in the Dynatech MR600 microplate reader (Dynatech Laboratories, Alexandria, Va., U.S.A.) using as a blank a well to which no HRP-MAb was added. Neutral&ation assays. For persistent fraction determinations, virus (5 × 106 to 1 × 10 v p.f.u./ml) was incubated for 60 min at 25 °C with an equal volume of MAb [diluted to 50 ~tg/~tl in Hanks' balanced salt solution (Gibco)]. Antibody to the nucleocapsid protein was used as a control. The dilution of the virus-antibody mixture, plating on chick embryo cells, and the overlay used for both virulent and avirulent strains have all been described previously (Iorio et al., 1984) .
RESULTS
MAb specificity, isotype and functional inhibition properties
A single fusion yielded 19 stable hybridomas producing NDV°specific MAbs. As shown in Fig. 1 , reducing SDS-PAGE of the proteins immunoprecipitated by these MAbs from [35S]methionine-labelled infected CHO cell lysates showed seven of these MAbs to be specific for the HN glycoprotein, while one MAb (55D7) was specific for the F glycoprotein. The remaining 11 were specific for either the nucleocapsid protein (NP) or the phosphoprotein (P) (data not shown).
The anti-HN MAbs showed a predominance of the IgG2a subtype (Table 1) as did our previous panel (Iorio & Bratt, 1983) . All of these anti-HN MAbs neutralized viral infectivity, but generally left even greater persistent fractions than our previous panel (Iorio & Bratt, 1984b) . Like the site 1 and site 2 MAbs (Iorio & Bratt, 1983) , only the six MAbs to site 1,4 (HN1,4 a to HN 1,4f) inhibited haemagglutination.
CAB assays
Our initial panel of MAbs had delineated four antigenic sites on HN as indicated by reciprocal CAB assays. The eight new anti-HN MAbs, and representative MAbs (HN 1 a, HN2a, HN3a and HN4b), each specific for one of the four previously defined antigenic sites on HN, were conjugated with horseradish peroxidase for use in CAB-ELISA. An ascites preparation of each of the MAbs was used in reciprocal CAB assays to determine the site specificity of the newly isolated anti-HN MAbs ( Table 2) . Six of them, HN1,4~, HNI,4b, HN1,4c, HN1,4d, HN1,4e and HN1,4~, were each able reciprocally to block the binding of one another; they therefore recognized overlapping determinants. Moreover, as shown in Table 2 , each of these six MAbs competed for the binding of MAbs to both sites 1 and 4 (which did not compete for each other's binding) and vice versa, but MAbs to sites 2 and 3 did not compete with, nor was their binding blocked by, any of this group. Thus, the site recognized by this group of MAbs topologically overlapped both sites 1 and 4.
Similarly, HN3,, HN3b and HN3c competed for overlapping sites on HN, as evidenced by their ability to block in a completely reciprocal manner. Thus, the additional panel of eight anti-HN MAbs recognized two non-overlapping sites: the previously described site 3, and site 1,4 which overlapped with the previously described, but mutually non-overlapping, sites 1 and 4. The new site 3 MAbs also showed the same previously described (Iorio & Bratt, 1983 ) partial competition with site 2 MAbs exhibited by HN3~ and no competition with MAbs to sites 1 and 4 ( Table 2) .
Variant analysis of HN site 1,4
To identify distinct epitopes recognized by MAbs to site 1,4, non-neutralized variants were selected with several of the MAbs to that site. Using this approach to delineate epitopes within predefined sites, we felt confident in concluding that an MAb that neutralized a variant selected with another MAb must have bound to an epitope distinct from that recognized by the selecting MAb. On the other hand, an MAb that did not neutralize a variant selected with a second MAb, may or may not (as will be shown below for MAbs HN3b and HN3~) have recognized the same epitope. Iorio & Bratt (1983 , 1984b .
The large persistent fraction of non-neutralized virus surviving M A b treatment (Table 1 ) necessitated the use of rabbit anti-mouse immunoglobulin to neutralize sensitized virus in order to make possible the isolation of variants (Iorio & Bratt, 1985) . Using this protocol, variants were selected with M A b s H N 1,4b, H N 1,4c and H N 1,4e and assayed for neutralization by all six M A b s to site 1,4, as well as by the previously characterized H N l b and HN4b MAbs, which recognized epitopes in sites 1 and 4, respectively ( (Iorio & Bratt, 1984a, c) .
Variant analysis of site 3
Variants were also selected with the three MAbs mapped to site 3. Screening the variants for neutralization by each of the site 3 MAbs revealed two distinguishable patterns, suggesting that they recognized two distinct epitopes: one defined by HN3a, and one by HN3b and HN3¢ (Table 4 ). (As indicated in the following section, however, by using a ts mutant, it was possible to show that HN3b and HN3e in fact recognized epitopes distinct from each other.) 
Neutralization of a ts mutant to identify distinct epitope recognition by MAbs HN3b and HN3c
A panel of ts mutants comprising six complementation groups were previously isolated from NDV strain AV in our laboratory (Tsipis & Bratt, 1976 ). Subsequently, it was shown that the mutants in three of these groups (B, C and BC) all had lesions in the gene coding for the HN glycoprotein (Peeples & Bratt, 1982; Peeples et al., 1981 Peeples et al., , 1983 . When each of the 11 mutants in the above three complementation groups was screened for neutralization by all of the previously described (Iorio & Bratt, 1983 ) and newly isolated MAbs (data not shown), only ts mutant BC3 could completely survive treatment with any of the MAbs. In fact, both HN3a and HN3b failed to neutralize mutant BC3 (Table 4 ). This does not per se preclude the possibility that the mutant may still have bound these MAbs despite the lack of neutralization. However, since virions of many of the ts mutants had reduced amounts of HN, it is not feasible to measure accurately the binding of MAbs to virions in the RIA. However, it appeared that the failure of HN3a and HN3b to neutralize mutant BC3 was indeed due to a failure to bind, since RAM treatment (Iorio & Bratt, 1985) of these virus-MAb mixtures did not result in neutralization (data not shown). The other MAb to site 3, HN3c, neutralized the mutant. This established that mutant BC3 had an alteration in, or was important to, the epitopes recognized by HN3a and HN3b but, more importantly, it allowed us to assign MAbs HN3b and HN3c to distinct epitopes, which could not be distinguished solely on the basis of the reciprocal neutralization patterns for variants and selecting MAbs (Table 3) . Iorio et al. (1984) . The neutralization with the homologous and 11 heterologous virus strains is plotted radially from the same central point with the scale indicating 100~ neutralization.
Neutralization of infectivity o f various ND V strains
As a measure of the extent to which each epitope was conserved in different strains, each of the MAbs was assayed for its ability to neutralize six virulent and five avirulent NDV strains. Table 5 shows the results with each of the eight MAbs. The data for MAbs recognizing the same epitope are indicated by braces and these showed similar patterns. The data are also plotted for one MAb to each epitope in the visual form modified (Iorio & Bratt, 1983 ) from that originally described by Nishikawa et al. (1983) (Fig. 2 and 3 ). On the basis of these results, MAb HN1,4~ was designated as specific for an epitope distinct from that recognized by MAbs HN1,4d, HN 1,4e and HN 1,4f, since compared to the latter strains, it left much greater persistent fractions with certain of the strains (most notably RO, E, N, U and W). Thus, differences in recognition of different strains by MAbs provided another criterion which could be used to distinguish epitopes. We have thus delineated three epitopes in site 1,4: one recognized by HN 1,4a (not distinguishable by the variant analyses in Table 3 ), one recognized by HN 1,4 b and HN 1,4c , and one by HN1,4d, N1,4e and HN1,4f. These three epitopes were, with the general exception of strain IM, essentially conserved in all the heterologous strains. In addition, there was the possibility that MAb HN 1,4f actually recognized an epitope distinct from that recognized by HN 1,4d and HN 1,4e because HN 1,4f neutralized AV much better than either of the other two MAbs (Tables 1 and 5 ).
MAbs to the two newly defined epitopes in site 3 presented a different pattern of neutralization with the heterologous strains compared with those shown for MAbs to site 1,4. With little exception, the epitopes recognized by MAbs HN3b and HN3e were not conserved. HN3 b neutralized none of the heterologous strains, whereas HN3c neutralized only very few of them (Table 5 and Fig. 3) . Thus, as we have already shown for the epitope recognized by one MAb (HN3,) to site 3 (Iorio et al., 1984) (reproduced in Fig. 3) , two additional epitopes in this site were extremely divergent in the heterologous strains especially in comparison to the epitopes recognized by MAbs to sites other than site 3. R. M. IORIO AND OTHERS Virulent  AV  460  460  700  340  130  160  170  220  130  430  290  F  310  420  880  440  150  130  130  280  <2  190  240  HP  310  260  330  160  130  90  130  190  <3  <20  <20  IM  490  20  70  120  30  <10  <50  140  6  <20  130  IS  -940  1750  620  580  340  120  --<70  450  L  450  910  1350  630  310  200  120  290  7  400  340  RO  410  30  130  300  250  80  150  240  <3  250  270  Avirulent  B  360  240  370  180  150  90  90  210  <6  350  290  E  -16  440  350  43  60  110  --< 10 <10  N  330  350  350  150  80  80  110  160  42  380  370  U  -11  470  420  50  48  190  --70  170  W  270  650  470  270  90  80  160  150  <3 480 340 * The reciprocal of the dilution of ascites fluid at the mid-point of the exponential part of a semi-log plot of c.p.m, bound against dilution of ascites fluid.
t Reproduced from Iorio et al. (1984) .
Failure of a MAb to neutralize need not necessarily be due to failure to bind to virions. Indeed, we have isolated variants which retained their infectivity in spite of binding the MAb used to select them (Iorio & Bratt, 1985) . Thus, the finding that heterologous strains were not neutralized by MAbs to site 3 cannot per se be taken as an indication of a failure of those MAbs to bind to the virus. Therefore, binding of MAbs HN3b and HN3c to each of the strains was assayed in the solid-phase RIA. The data (Table 6) show that HN3b and HN3c could indeed bind to most of the heterologous strains which they were unable to neutralize (Table 5) . Thus, binding and neutralization were separable properties with respect to the interaction of these MAbs and heterologous strains. Moreover, the finding that HN3a did not bind to the heterologous strains provided further evidence for its specificity for an epitope different from that recognized by HN3b and HN3c.
As another means of detecting MAb binding in the absence of neutralization, selected MAbstrain pairs were subjected to RAM treatment. We have previously shown (Iorio & Bratt, 1985) that this treatment can neutralize variants 'sensitized', but not neutralized, by a MAb. The persistent fractions of virus surviving MAb and RAM treatment are shown in parentheses in Table 5 next to those remaining when the strain was treated with the MAb alone. A number of instances could be seen (most notable with strains F, IS, L and RO) in which the MAbs HN3b and HN3c neutralized a strain's infectivity only when RAM treatment was used. Similar results were seen in the interaction of several MAbs to site 1,4 with strain IM (Tables 5 and 6) . Moreover, these data agreed quite well with the RIA binding sites (Table 6 ). However, there were exceptions, most notably MAbs HN3b and HN3c, which did not bind in the RIA to strains IS and HP, respectively, but were neutralized upon treatment with RAM. This probably meant that binding in the RIA and neutralization by RAM did not measure the same phenomenon in the interaction of MAbs with heterologous strains.
DISCUSSION
WC have used a new panel of MAbs to extend our initial studies on variation in the HN glycoprotcin of diffcrcnt NDV strains (Iorio et al., 1984) . Our panel of MAbs to the HN of NDV strain AV now encompasscs a total of 17 antibodies: thrcc spccific for site l, two specific for site 2, thrcc specific for sitc 3, three specific for site 4, and six spccific for a site (1,4) which overlaps thc originally dcfincd sites I and 4. These sites have bccn further subdivided into a total of nine cpitopes determined in part by the standard analysis of neutralization of antigenic variants selected by MAbs and in part by thrcc approachcs not previously described, namcly neutralization of a ts mutant by MAbs, ncutralization of hctcrologous strains, and the binding of MAbs to variants as mcasurcd either in an RIA or by scnsitization of virus to ncutralization by RAM.
Six of thc eight newly dcscribcd anti-HN MAbs compete for the binding of MAbs to both sites I and 4 from our initial pancl. Having dcfined the four HN sitcs with our initial pancl of MAbs (Iorio & Bratt, 1983) , wc have continued with that nomenclature and thus havc dcsignatcd as site 1,4 the site recognized by thcsc six new MAbs. However, these MAbs may in rcality bc site I MAbs which, when bound to HN, block the binding of site 4 MAbs either physically or by inducing a conformational change in site 4. This vicw is supported by thc HA inhibitory activity of these MAbs: both site 1,4 and site l, but not sitc 4, MAbs (Iorio & Bratt, 1984a, c) inhibit HA. Also, variants sclcctcd with some site 1,4 MAbs arc not neutralized by HNIb and vice versa, while all site 1,4 variants arc neutralized by HN4 b and vice versa. Thus, it seems likely that the sitc 1,4 MAbs only stcrically or conformationally block site 4, but do not bind within site 4 itself (as wc had previously defined it). Significantly, this may place the two sites closcr to one another than our original findings had suggested (Iorio & Bratt, 1984a, c) .
Our panel of MAbs to the HN of NDV strain AV now idcntifics a total of at least nine cpitopcs, three of which, localized to site 3, arc divergent, while all six outside site 3 arc conscrvcd in hctcrologous strains. Nonetheless, thcsc data mean that our original observation of considerable variation in one epitopc in site 3 (Iorio et al., 1984) is actually a property of a more cxtcnsivc domain in site 3 of thc HN glycoprotcin of NDV strain AV. That this cxtcnsivc variation at a site like sitc 3 which wc have defined for strain AV is in fact a reflection of a general phenomenon with NDV's HN is suggested by strain comparison data in another laboratory. Nishikawa et al. (1983) , using antibodies to three epitopcs on the HN of the Dz6 strain found one which is conscrvcd and two others which arc not conserved in thc hctcrologous strains.
Thc data presented hcrc introduce a number of findings not seen previously. The intcraction of MAbs HN3b and HN3c with several virulent and avirulcnt strains is unique in that binding of the MAb to the virus (as assayed by RIA or after RAM treatment) docs not affect the neutralization of infectivity (Tables 5 and 6 ). Thus, the cpitopcs rccognizcd by thcsc MAbs arc present on the HNs of thc hcterologous strains, but arc not ncutralizing. There arc at least three possible explanations for this phenomenon. It may bc that the cpitopc is intact in the hctcrologous strains but no longer at a position in the three-dimensional conformation of HN where it can block infectivity, i.e. the epitope is not neutralizing in the heterologous strains. Alternatively, one must consider the possibility, unlikely though it may seem, that the size of the persistent fraction depends on a characteristic of the virus preparation (such as density of HN on virions or virion avidity for cell receptors) which is strain-specific at a single epitope. Finally, there is the possibility that the MAbs may bind to heterologous strains with a lower avidity. The latter seems less likely since the RIA curves for MAbs HN3b and HN3c with AV and with the heterologous strains do not differ significantly (data not shown). Thus, as we have suggested for two variants which bind selecting MAb but are not neutralized (Iorio & Bratt, 1985) , it is more likely that the epitope recognized by these MAbs is intact but in a different position in the configuration of HN.
Among the heterologous strains, IM stands out, differing markedly from AV at each of the site 1,4 epitopes. Furthermore, in some cases certain MAbs bind to strain IM without neutralization (Tables 5 and 6), as already discussed for the two epitopes in site 3. This distinction was not apparent in our initial study (Iorio & Bratt, 1983) with MAb HN3a.
The data herein have enabled us (i) to identify a new antigenic site, 1,4, which overlaps with previously defined sites 1 and 4, a result suggesting a closer association of the latter than previously expected, (ii) to establish a high degree of strain-specific variation in a multi-epitopic domain within site 3, and (iii) to demonstrate that ts mutants and heterologous strains, as well as MAb binding (determined by either RIA or RAM treatment), can be used as a new means of identifying separable epitopes within an antigenic site.
